Industry
Biotechnology
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
52.36
Mkt cap
3.1B
Volume
78K
High
54.11
P/E Ratio
4.63
52-wk high
62.58
Low
52.09
Div yield
N/A
52-wk low
20.96
Portfolio Pulse from Benzinga Insights
November 01, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 4:33 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 2:20 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:36 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 10:40 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 10:32 am
Portfolio Pulse from Benzinga Insights
October 30, 2024 | 2:03 pm
Portfolio Pulse from Benzinga Newsdesk
October 23, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 2:24 pm
Portfolio Pulse from Benzinga Insights
October 10, 2024 | 2:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.